FDA Grants Rybrevant Faspro Accelerated Approval in HNSCC

Source-gap recovery: on November 5, 2026, the US FDA granted Janssen Biotech accelerated approval for subcutaneous amivantamab and hyaluronidase-lpuj as monotherapy after platinum chemotherapy and anti-PD-(L)1 therapy in specified recurrent or metastatic head and…




